Chugai Pharma announced preclinical results for their antibody, DONQ52, published in Nature Communications.

Fast track designation (FTD) is a process used by the U.S. Food and Drug Administration (FDA) tofacilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

LegoChem Biosciences announced a licensing deal with Janssen Biotech to develop and market LCB84, a Trop2-targeted antibody-drug conjugate.

5-HT1A receptor agonists are drugs that activate the 5-HT1A receptor, used in treating conditions like anxiety, depression, and schizophrenia.

Zealand Pharma has officially presented a request for drug approval to the United States' FDA for their medication glepaglutide, aiming to treat individuals with short bowel syndrome.

The U.S. FDA offers Fast Track Designation and Breakthrough Therapy Designation to speed up the development and review of drugs for serious conditions lacking treatments. Yet, they differ in key aspects.

Senti Bio has received the green light from the FDA for SENTI-202, aimed at addressing recurring or stubborn blood cancers, such as Acute Myeloid Leukemia.

MR(Mineralocorticoid Receptor) antagonists are drugs that block the mineralocorticoid receptor, aiding in the treatment of hypertension and heart failure.

Tyra Biosciences successfully administered the inaugural dose of TYRA-200 to a patient and shared encouraging progress on their TYRA-300 development.

Protein palmitoylation is a post-translational modification that involves the addition of a 16-carbon saturated fatty acid, typically palmitate (C16:0), to cysteine residues within target proteins.

U.S. health authorities expedite assessment of Patritumab Deruxtecan for select cases of advanced or widespread EGFR-altered Non-Small Cell Lung Cancer after first treatments.

Histamine receptor antagonists are drugs that block histamine action, relieving allergic reactions.